Conference Reports for NATAP

AASLD 61th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA, Hynes Convention Center October 30-November 3, 2010 Back

Safety, Pharmacokinetics, and Antiviral Activity of Single Oral Doses of the HCV NS3 Protease Inhibitor GS-9256       Reported by Jules Levin AASLD 2010 Nov 2 Boston   R Goldwater1, M DeMicco2, J Zong3, G Chittick3, G Yuen3, S West3, J Kagel3, A Bae3, H Mo3, D Oldach3, W Delaney3, and J Findlay3 1PAREXEL International, Baltimore, MD, 2Advanced Clinical Research Institute, Anaheim, CA, 3Gilead Sciences, Foster City, CA.